Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes (Q38218644)

31 August 2017

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes (English)

1 reference

31 August 2017

0 references

0 references

0 references

1 reference

3

Robert M Califf

1 reference

31 August 2017

Rury R Holman

1

1 reference

PubMed ID

24910232

31 August 2017

Harald Sourij

series ordinal

2

1 reference

PubMed ID

24910232

31 August 2017

language of work or name

English

0 references

publication date

1 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

383

1 reference

31 August 2017

2008-2017

1 reference

31 August 2017

9933

1 reference

Diabetes mellitus, fasting glucose, and risk of cause-specific death

31 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

A randomized trial of therapies for type 2 diabetes and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Basal insulin and cardiovascular and other outcomes in dysglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Severe hypoglycemia and risks of vascular events and death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

The prevention and treatment of missing data in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Withdrawing from the treatment does not mean from the study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

A method to reduce loss to follow-up in clinical trials: informed, withdrawal of consent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

PCORI at 3 years--progress, lessons, and plans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Thrombus aspiration during ST-segment elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

The randomized registry trial--the next disruptive technology in clinical research?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Individualized medicine from prewomb to tomb

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Forging stronger partnerships between academic health centers and patient-driven organizations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960794-7

7 January 2021

10.1016/S0140-6736(14)60794-7

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24910232